Dr. Muggia on Targeted Therapies in Ovarian Cancer

Franco M. Muggia, MD, professor of oncology, New York University, director, Division of Medical Oncology, New York University Medical Center, discusses the challenge of developing targeted therapies to treat ovarian cancer.

NYU Langone

Franco M. Muggia, MD, Franco M. Muggia, MD, The Anne Murnick Cogan and David H. Cogan Professor of Oncology, Medical Center, discusses the challenge of developing targeted therapies to treat ovarian cancer.

Muggia says drug development in ovarian cancer has not been easy, resulting in a lack of targeted therapies. Physicians rely on a chemotherapy regimen to treat patients with ovarian cancer that eliminates advanced disease about 80-90% of the time. However, Muggia says, the disease eventually comes back.

Muggia says there is a need to improve treatment for ovarian cancer. BRCA and PARP targets have proven to be good targets to develop further.

Related Content:

NYU Langone's Perlmutter Cancer CenterOncLive TVOvarian CancerPrecision Medicine in Oncology®
Dr Pant on the Importance of Targeted Therapy and Mutation Testing in Pancreatic Cancer
Dr Ecker on the Role of CAPETEM in the Treatment of Pancreatic NETs
Dr Garmezy on Findings From the Duravelo-1 Trial in Metastatic Urothelial Carcinoma